ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient (“API”) for VIVUS’ Qsymia™, a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012.

ScinoPharm (TWSE:1789) announced today that it will invest NT$1.1 billion (approximately US$37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company’s premise at the Tainan Science Park.

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), today announced the appointment of Nana Hsieh Hung as Vice President of Administration. She will report directly to Dr. Jo Shen, President and CEO of ScinoPharm.

ScinoPharm Taiwan, Ltd. (TWSE1789) a leading global supplier of active pharmaceutical ingredients (APIs), announced unaudited revenues totaling NT$3.948 billion for 2011, and before-tax net profits of NT$1.124 billion, for an EPS of $1.82.